Evolus Inc Dossier - Source-backed chat

Evolus Inc

EOLSNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.24

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.69Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $507.9M

Enterprise Value $619.5M

Shares Outstanding 65.9M diluted

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Evolus, Inc. is successfully transitioning from a single-product neurotoxin player into a multi-product global aesthetics platform. By leveraging its highly efficient, digitally enabled, cash-pay commercial infrastructure, the company is driving sustained market share gains for Jeuveau while rapidly scaling its newly launched Evolysse (U.S.) and Estyme (Europe) hyaluronic acid (HA) filler portfolios. The company's strong operating leverage is demonstrated by its second consecutive quarter of positive Adjusted EBITDA in Q1 2026, positioning it well for sustainable full-year profitability.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$14.67

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Macroeconomic headwinds or a slowdown in consumer discretionary spending dampens self-pay aesthetic procedures. Intense competitive discounting from established players limits Jeuveau's market share gains, while regulatory delays for Evolysse Sculpt push the U.S. launch into 2027. Additionally, potential tariff headwinds on imported products from South Korea compress gross margins.

Base CaseCentral scenario

Evolus continues to capture market share in the aesthetic neurotoxin space, maintaining a 14% U.S. share while expanding internationally. The commercial launch of the Estyme HA gel collection in Europe (May 2026) and the anticipated late-2026 U.S. approval of Evolysse Sculpt drive high-margin product diversification. Operating leverage expands as non-GAAP operating expenses grow at a modest 0% to 3% rate, leading to positive Adjusted EBITDA and low-to-mid single-digit margins for the full year 2026.

Bull CaseUpside scenario

The bull case for Evolus rests on its transition to disciplined expansion and a clear path to profitability, driven by its strong commercial model with high reorder rates and expanding account penetration. Key growth drivers include the successful rollout of the Evolysse dermal filler line and the anticipated FDA approval of Sculpt to diversify its portfolio beyond Jeuveau, alongside strategic international expansion into high-growth European markets to capture a larger share of the lucrative aesthetics market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated cash-pay business model that avoids reimbursement complexities and targets highly engaged, younger beauty consumers.
Strong customer loyalty and retention, supported by the rapidly growing Evolus Rewards program approaching 1.5 million members.
Expanding product portfolio with the launch of the Estyme HA filler line in Europe and upcoming U.S. approval of Evolysse Sculpt.
Demonstrated operating leverage, achieving positive Adjusted EBITDA for two consecutive quarters (Q4 2025 and Q1 2026) with disciplined expense management.

Key Investment Risks

High concentration of revenue in the aesthetic neurotoxin market, leaving the company vulnerable to competitive pricing pressure.
Regulatory risks associated with the approval timeline of pipeline products like Evolysse Sculpt and Evolysse Lips.
Exposure to international supply chain and tariff risks, including a 10% tariff on imported Evolysse products and potential South Korean pharmaceutical tariffs.

Thesis Invalidation Triggers

A significant drop in the customer reorder rate below 65%, indicating loss of practitioner engagement.
FDA rejection or prolonged delay of the Premarket Approval (PMA) application for Evolysse Sculpt.
Failure to maintain positive Adjusted EBITDA in subsequent quarters of 2026, signaling a breakdown in operating leverage.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.